


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Compounds~~ A compound of the general formula I



in which

- R^1 is H or A,
 $R^{2'}$, $R^{2''}$, $R^{2'''}$ are each, independently of one another, H, A, OH, OCH₃, OCF₃, Hal, CN, COOR¹, CONR¹ or NO₂,
 R^3 is A, Ar or A-Ar,
 R^4 is H or A,
A is unbranched or branched alkyl having 1-10 carbon atoms, in which one or two CH₂ groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or 1-7 H atoms may also be replaced by F,
Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR⁴, N(R⁴)₂, NO₂, CN, COOR⁴, CON(R⁴)₂, NR⁴COA, NR⁴CON(R⁴)₂, NR⁴SO₂A, COR⁴, SO₂N(R⁴)₂ or SO₂A,
A-Ar is arylalkyl, where A and Ar have one of the above-mentioned meanings,
Hal is F, Cl, Br or I, and
n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10,

~~and solvates, stereoisomers and pharmaceutically usable derivatives, thereof, including mixtures thereof in all ratios~~ or a pharmaceutically acceptable salt thereof.

2. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, in which R^1 is hydrogen, ~~and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios.~~


3. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, in which R²ⁱ, R²ⁿ, R^{2m} are hydrogen, and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios.

4. (Currently Amended) ~~Compounds~~ A compound according to ~~claim 1~~ claim 1, in which R³ is n-propyl, i-propyl, n-butyl, 2,2,2-trifluoroethyl, phenyl, benzyl or 2-nitrophenylmethyl, and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios.

5. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which n is 1, and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios.


6. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, which is selected from the group consisting of
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-C-phenylmethanesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-C-[2-nitrophenyl]methanesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]benzenesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-2-propanesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-butanesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-propanesulfonamide, or
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-2,2,2-trifluoroethanesulfonamide,
~~and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including~~
mixtures thereof in all ratios or a pharmaceutically acceptable salt thereof.

7. (Currently Amended) ~~Process for the preparation of compounds of the~~
A process for preparing a compound of formula I according to claim 1 and pharmaceutically
~~usable derivatives, solvates and stereoisomers thereof, characterised in that or a~~
pharmaceutically acceptable salt thereof, comprising
a) reacting a compound of the formula V




V,


in which R is a nucleophilic leaving group usually employed suitable for nucleophilic substitutions substitution on an aromatic compounds, is reacted compound with a compound of the formula VI



in which R^{2'}, R^{2''}, R^{2'''} and n are as defined in Claim 1 for the compound of formula I, giving a compound of the formula IV



b) ~~the resultant phenoxy piperidine of the~~ converting the compound of formula IV is converted by hydrogenation and optionally alkylation into a compound of the formula II



in which R¹ is as defined in Claim 1 for the compound of formula I, which is then

c) reacted ~~further~~ with a compound of the formula III

Error! Bookmark not defined. III,

in which R³ is as defined in Claim 1 for the compound of formula I, and L is a nucleophilic leaving group ~~known per se~~, giving a compound of the formula I,

and optionally a protecting group is subsequently cleaved off,

and/or a base or acid of the a compound of formula I is converted into one of its salts.

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Currently Amended) Medicaments A pharmaceutical composition
comprising ~~at least one a~~ compound of the formula I according to claim 1, and/or or a
pharmaceutically usable derivatives, solvates and stereoisomers acceptable salt thereof,
~~including mixtures thereof in all ratios, according to claim 1, and optionally excipients a~~
pharmaceutically acceptable excipient and/or adjuvants adjuvant.

12. (Currently Amended) Medicaments A pharmaceutical composition
according to claim 11, further comprising ~~comprising at least one compound of the formula I~~
~~and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including~~
~~mixtures thereof in all ratios, according to, and at least one further medicament~~
pharmaceutically active ingredient.

13. (Withdrawn and Currently Amended) ~~Use of compounds according to~~
~~claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios, for the preparation of a medicament~~ A method for the
prophylaxis or treatment of diseases a disease in which the binding of ~~one or more active~~
~~ingredients present in the said medicament~~ a compound of formula I according to claim 1 or a
pharmaceutically acceptable salt thereof to a nicotinic and/or muscarinic acetylcholine
receptor receptors leads to an improvement in the clinical picture comprising administering to
a patient in need thereof an effective amount of the compound of formula I or a
pharmaceutically acceptable salt thereof.

14. (Withdrawn and Currently Amended) ~~Use of compounds according to~~
~~claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios, for the preparation of a medicament~~ A method for the
prophylaxis or treatment of schizophrenia, depression, an anxiety states state, dementia,
Alzheimer's disease, Lewy bodies dementia, a neurodegenerative diseases disease,
Parkinson's disease, Huntington's disease, Tourette's syndrome, a learning and or memory
~~impairments~~ impairment, age-related memory impairment, amelioration of withdrawal

symptoms in nicotine dependence, ~~strokes~~ stroke or brain damage by ~~a toxic compounds~~ compound, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 11.

15. (Cancelled)

16. (Currently Amended) ~~Process for the preparation of~~ A process for preparing a pharmaceutical composition ~~comprising at least one compound~~ according to ~~claim 1~~ claim 11, comprising converting said composition into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

17. (Withdrawn and Currently Amended) ~~Set (kit) consisting of~~ A set or kit comprising separate packs of

(a) an effective amount of a compound of the formula I according to ~~and/or claim 1 or a pharmaceutically usable derivatives, solvates and stereoisomers~~ acceptable salt thereof, including ~~mixtures thereof in all ratios~~, and

(b) an effective amount of a further medicament pharmaceutically active ingredient.


18. (Withdrawn and Currently Amended) ~~Use of compounds of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, according to claim 1, for the preparation of a medicament for the prophylaxis or treatment of schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative diseases, Parkinson's disease, Huntington's disease, Tourette's syndrome, learning and memory impairments, age-related memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds, in combination with at least one further medicament active ingredient~~ A method for the prophylaxis or treatment of schizophrenia, depression, an anxiety state, dementia, Alzheimer's disease, Lewy bodies dementia, a neurodegenerative disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, a learning or memory impairment, age-related memory impairment, amelioration of withdrawal symptoms in nicotine dependence, stroke or brain damage by a toxic compound, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.

19-20. (Cancelled)

21. (New) An isolated stereoisomer of a compound of formula I according to claim 1.

22. (New) A mixture of stereoisomers of a compound of formula I according to claim 1.

23. (New) A compound of formula I



in which

R^1 is H or A,

$R^{2'}$, $R^{2''}$, $R^{2'''}$ are each, independently of one another, H, A, OH, OCH_3 , OCF_3 , Hal, CN, $COOR^1$, $CONR^1$ or NO_2 ,

R^3 is A, Ar or A-Ar,

R^4 is H or A,

A is unbranched or branched alkyl having 1-10 carbon atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by $-CH=CH-$ groups and/or 1-7 H atoms may be replaced by F,

Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^4 , $N(R^4)_2$, NO_2 , CN, $COOR^4$, $CON(R^4)_2$, NR^4COA , $NR^4CON(R^4)_2$, NR^4SO_2A , COR^4 , $SO_2N(R^4)_2$ or SO_2A ,

A-Ar is arylalkyl, where A and Ar have one of the above-mentioned meanings,

Hal is F, Cl, Br or I, and

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10,

or a pharmaceutically acceptable salt or solvate thereof.

24. (New) A compound according to claim 23, wherein the solvate is a mono- or dihydrate or alcoholate.